Literature DB >> 11138930

Cholesterol is sequestered in the brains of mice with Niemann-Pick type C disease but turnover is increased.

C Xie1, D K Burns, S D Turley, J M Dietschy.   

Abstract

In Niemann-Pick Type C (NPC) disease, the concentration of cholesterol increases with age in every tissue except the brain. This study investigates whether accumulation of cholesterol might also occur within the cells of the central nervous system (CNS), but be obscured by the simultaneous loss of sterol from myelin as neurodegeneration proceeds. At birth, when there is little myelin in the CNS, the concentration of cholesterol is significantly elevated in every region of the brain in the homozygous NPC mouse. At 7 wk of age, myelination is nearly complete. In the NPC mouse, however, there is striking neurodegeneration and a reduction in both myelin protein and myelin cholesterol. Furthermore, net loss of cholesterol from the CNS is much higher in the NPC mouse than in the control animal (2.23 versus 1.37 mg/day per kg) so that the concentration of sterol in most regions of the brain is reduced. This neurodegeneration and loss of myelin cholesterol is not prevented by deletion of either the low-density lipoprotein receptor or apolipoprotein E in the NPC animal. Thus, the cholesterol sequestration seen in every organ in NPC disease also occurs in cells of the CNS and may be etiologically related to the neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138930     DOI: 10.1093/jnen/59.12.1106

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  41 in total

1.  Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1.

Authors:  Stephen D Turley; Mark A Valasek; Joyce J Repa; John M Dietschy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

2.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

3.  Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream.

Authors:  Anna M Taylor; Bing Liu; Yelenis Mari; Benny Liu; Joyce J Repa
Journal:  J Lipid Res       Date:  2012-08-14       Impact factor: 5.922

4.  Generation of a human neuronal stable cell model for niemann-pick C disease by RNA interference.

Authors:  Laura Rodríguez-Pascau; Maria Josep Coll; Josefina Casas; Lluïsa Vilageliu; Daniel Grinberg
Journal:  JIMD Rep       Date:  2011-11-01

Review 5.  Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia.

Authors:  Robert P Erickson
Journal:  J Appl Genet       Date:  2013-01-05       Impact factor: 3.240

6.  Mass spectrometry imaging of lipids: untargeted consensus spectra reveal spatial distributions in Niemann-Pick disease type C1.

Authors:  Fernando Tobias; Matthew T Olson; Stephanie M Cologna
Journal:  J Lipid Res       Date:  2018-09-28       Impact factor: 5.922

7.  Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis.

Authors:  Chris D Pacheco; Matthew J Elrick; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

8.  GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice.

Authors:  Hao Li; Stephen D Turley; Benny Liu; Joyce J Repa; John M Dietschy
Journal:  J Lipid Res       Date:  2008-04-30       Impact factor: 5.922

9.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid.

Authors:  Benny Liu; Charina M Ramirez; Anna M Miller; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2009-11-18       Impact factor: 5.922

Review 10.  The pathogenesis of Niemann-Pick type C disease: a role for autophagy?

Authors:  Chris D Pacheco; Andrew P Lieberman
Journal:  Expert Rev Mol Med       Date:  2008-09-10       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.